Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2001 1
2005 2
2006 4
2007 2
2008 2
2009 4
2010 2
2011 1
2012 1
2013 4
2014 3
2015 10
2016 11
2017 7
2018 9
2019 5
2020 17
2021 15
2022 19
2023 17
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Results by year

Filters applied: . Clear all
Page 1
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Silverberg JI, et al. N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. N Engl J Med. 2023. PMID: 36920778 Clinical Trial.
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators. Simpson EL, et al. N Engl J Med. 2016 Dec 15;375(24):2335-2348. doi: 10.1056/NEJMoa1610020. Epub 2016 Sep 30. N Engl J Med. 2016. PMID: 27690741 Free article. Clinical Trial.
Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results.
Pereyra-Rodríguez JJ, Herranz P, Ruiz-Villaverde R, Elosua-González M, Galán-Gutiérrez M, Figueras-Nart I, Miquel J, de la Cueva P, Serra-Baldrich E, Munera-Campos M, Melé-Ninot G, Expósito-Serrano V, Perez B, Serrano A, Ortiz de Frutos JF, Armario-Hita JC. Pereyra-Rodríguez JJ, et al. Among authors: de la cueva p. Clin Exp Dermatol. 2023 Aug 25;48(9):991-997. doi: 10.1093/ced/llad153. Clin Exp Dermatol. 2023. PMID: 37098171
Moderate Psoriasis: A Proposed Definition.
Llamas-Velasco M, de la Cueva P, Notario J, Martínez-Pilar L, Martorell A, Moreno-Ramírez D. Llamas-Velasco M, et al. Among authors: de la cueva p. Actas Dermosifiliogr. 2017 Dec;108(10):911-917. doi: 10.1016/j.ad.2017.07.002. Epub 2017 Aug 17. Actas Dermosifiliogr. 2017. PMID: 28823420 Free article. Review. English, Spanish.
Primary follicular mucinosis in childhood.
Valdivielso-Ramos M, Alonso S, Sanchez B, Carrascosa R, Galiano S, Silvente C, de la Cueva P. Valdivielso-Ramos M, et al. Among authors: de la cueva p. Int J Dermatol. 2021 May;60(5):e197-e199. doi: 10.1111/ijd.15309. Epub 2020 Nov 9. Int J Dermatol. 2021. PMID: 33166091 No abstract available.
Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice.
Muñoz-Aceituno E, Butrón-Bris B, Ovejero-Benito MC, Sahuquillo-Torralba A, Baniandrés Rodríguez O, Herrera-Acosta E, Rivera-Diaz R, Ferran M, Sánchez-Carazo JL, Riera-Monroig J, Pujol-Montcusí J, Vidal D, de la Cueva P, García-Bustinduy M, Ruiz-Villaverde R, Ballescà F, Llamas-Velasco M, Navares M, Palomar-Moreno I, Sánchez-García I, García-Martínez J, Novalbos J, Zubiaur P, Abad-Santos F, Daudén-Tello E, de la Fuente H. Muñoz-Aceituno E, et al. Among authors: de la cueva p. J Eur Acad Dermatol Venereol. 2023 Dec 28. doi: 10.1111/jdv.19782. Online ahead of print. J Eur Acad Dermatol Venereol. 2023. PMID: 38153843
Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2 - Management of Special Populations, Patients With Comorbid Conditions, and Risk.
Carrascosa JM, Puig L, Romero IB, Salgado-Boquete L, Del Alcázar E, Lencina JJA, Moreno D, de la Cueva P. Carrascosa JM, et al. Among authors: de la cueva p. Actas Dermosifiliogr. 2022 Jun;113(6):583-609. doi: 10.1016/j.ad.2022.01.024. Epub 2022 Feb 11. Actas Dermosifiliogr. 2022. PMID: 35570005 Free article. Review. English, Spanish.
Expert recommendations on treating psoriasis in special circumstances.
Carrascosa JM, Belinchón I, de-la-Cueva P, Izu R, Luelmo J, Ruiz-Villaverde R. Carrascosa JM, et al. Among authors: de la cueva p. Actas Dermosifiliogr. 2015 May;106(4):292-309. doi: 10.1016/j.ad.2014.11.005. Epub 2015 Jan 14. Actas Dermosifiliogr. 2015. PMID: 25595327 Free article. Review. English, Spanish.
113 results